alpha-cyano-N-(2,5-dibromophenyl)-beta-hydroxybut-2-enamide

The title compound, C11H8Br2N2O2 (LFM-A13), is the first reported BTK-speci fic tyrosine kinase inhibitor and the first antileukemic agent targeting BT K (Bruton's tyrosine kinase). The crystal structure showed that the molecul e adopts an approximately planar conformation aided by an intramolecular hy drogen bond formed between the hydroxyl group and the amide carbonyl group. The dihedral angle between the phenyl ring and the plane defined by the N- C-C=C-CH3 group is 8.2(6)degrees. The crystal packing shows an additional w eak intermolecular hydrogen bond between the hydroxyl group and the amide c arbonyl-O atom of the centrosymmetrically related molecule.